The association of the vitamin D status with the persistence of anti-HBs antibody at 20 years after primary vaccination with recombinant hepatitis B vaccine in infancy - 08/02/17
, J. Keshavarz a, b, M. Bagheri-Jamebozorgi b, M. Nemati c, R. Frootan d, F. Shokri eBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 9 |
| Iconographies | 3 |
| Vidéos | 0 |
| Autres | 0 |
Summary |
Background and objective |
Vitamin D has potent immunoregulatory effects due to the expression of its receptor on the majority of immune cells. The aim was to evaluate the association of the vitamin D status with the persistence of anti-HBs antibody and immune response to booster immunization at 20years after primary vaccination with hepatitis B (HB) vaccine.
Methods |
Blood samples were collected from 300 adults 20years after completion of the primary HB vaccination in infancy. The serum levels of vitamin D and anti-HBs antibody were measured by ELISA. A single booster dose of a recombinant HB vaccine was administered to a total of 138 subjects, whose anti-HBs titer was<10IU/L. The sera of revaccinated subjects were re-tested for anti-HBs antibody, 4weeks after booster vaccination.
Results |
At 20years after primary vaccination, the mean vitamin D concentrations were significantly higher in seroprotective subjects as compared to non-seroprotective individuals (P<0.01). The levels of anti-HBs were significantly increased with advanced concentrations of vitamin D (P<0.01). Overall, 125/138 (90.6%) of the revaccinated subjects showed an anamnestic response to booster vaccination. The concentrations of vitamin D were significantly higher in subjects with an anamnestic response to booster vaccination as compared with subjects without this response (P<0.01).
Conclusion |
Vitamin D status may influence the persistence of anti-HBs antibody and durability of protection after primary vaccination with a recombinant HB vaccine in infancy.
Le texte complet de cet article est disponible en PDF.Plan
Vol 41 - N° 1
P. 66-74 - février 2017 Retour au numéro
Article précédent
- Efficacy and safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation (ANRS HC29 BOCEPRETRANSPLANT)
- Hélène Fontaine, Marianne Maynard, Cécile Bouix, Maria Patrizia Carrieri, Danielle Botta-Fridlund, Louis D’Alteroche, Filomena Conti, Georges-Philippe Pageaux, Vincent Leroy, Sophie Métivier, Rodolphe Anty, François Durand, Valérie Canva, Antoine Vilotitch, Pascal Lebray, Laurent Alric, Christophe Duvoux, Ventzislava Petrov-Sanchez, Frédérik Beaulieux, Célia Wellems, Christelle Paul, Anne-Marie Roque-Afonso, Bruno Roche, Pierre Pradat, Didier Samuel, Jean-Charles Duclos-Vallée
- Evaluation of drug-eluting beads versus conventional transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis
- Peng Chen, Peng Yuan, Bo Chen, Jingchang Sun, Hang Shen, Yeben Qian
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?